- Home
- ADIL vs GTBP Comparison
ADIL vs GTBP Comparison
Compare ADIL & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- GTBP
- Stock Information
- Founded
- ADIL 2010
- GTBP 1965
- Country
- ADIL United States
- GTBP United States
- Employees
- ADIL N/A
- GTBP N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- GTBP Health Care
- Exchange
- ADIL Nasdaq
- GTBP Nasdaq
- Market Cap
- ADIL 4.8M
- GTBP 5.5M
- IPO Year
- ADIL 2018
- GTBP N/A
- Fundamental
- Price
- ADIL $0.37
- GTBP $2.14
- Analyst Decision
- ADIL Strong Buy
- GTBP Strong Buy
- Analyst Count
- ADIL 1
- GTBP 1
- Target Price
- ADIL $8.00
- GTBP $11.00
- AVG Volume (30 Days)
- ADIL 23.1M
- GTBP 108.5K
- Earning Date
- ADIL 08-12-2025
- GTBP 08-13-2025
- Dividend Yield
- ADIL N/A
- GTBP N/A
- EPS Growth
- ADIL N/A
- GTBP N/A
- EPS
- ADIL N/A
- GTBP N/A
- Revenue
- ADIL N/A
- GTBP N/A
- Revenue This Year
- ADIL N/A
- GTBP N/A
- Revenue Next Year
- ADIL N/A
- GTBP N/A
- P/E Ratio
- ADIL N/A
- GTBP N/A
- Revenue Growth
- ADIL N/A
- GTBP N/A
- 52 Week Low
- ADIL $0.22
- GTBP $1.72
- 52 Week High
- ADIL $3.00
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- ADIL 46.63
- GTBP 38.82
- Support Level
- ADIL $0.30
- GTBP $1.91
- Resistance Level
- ADIL $0.41
- GTBP $3.73
- Average True Range (ATR)
- ADIL 0.06
- GTBP 0.33
- MACD
- ADIL 0.02
- GTBP -0.16
- Stochastic Oscillator
- ADIL 48.13
- GTBP 19.59
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.